JPH09278662A - Antiallergic agent - Google Patents
Antiallergic agentInfo
- Publication number
- JPH09278662A JPH09278662A JP8087980A JP8798096A JPH09278662A JP H09278662 A JPH09278662 A JP H09278662A JP 8087980 A JP8087980 A JP 8087980A JP 8798096 A JP8798096 A JP 8798096A JP H09278662 A JPH09278662 A JP H09278662A
- Authority
- JP
- Japan
- Prior art keywords
- antiallergic agent
- oil
- bamboo extract
- bamboo
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明はアレルギー性鼻炎
（花粉症）やアトピー性皮膚炎等のアレルギー症状の予
防および治療に効果のある抗アレルギー剤に関するもの
である。TECHNICAL FIELD The present invention relates to an antiallergic agent which is effective in preventing and treating allergic symptoms such as allergic rhinitis (hay fever) and atopic dermatitis.
【０００２】[0002]
【従来の技術】アレルギー症状は体内で起こる抗原抗体
反応による免疫グロブリンＥ（ＩｇＥ）の産生から、結
果的に肥満細胞の細胞膜を刺激し、ヒスタミン、ロイコ
トリエンを放出することによって起こる。放出されたこ
れらの物質は、血管透過性を促進させる作用や、平滑筋
を収縮させる作用などがあるため、白血球や蛋白質が血
管から漏出したり、炎症により気管支を収縮させ喘息を
起こしたりする。抗アレルギー成分に関して、ボルネオ
ールの肥満細胞膜安定化能（特開平６ー２１１７１３号
公報）、放線菌培養液の炎症抑制作用（特開平５ー２５
０５３号公報）を利用した技術が知られている。一方、
奥山らにより、ゴマ油を摂取することによって、アレル
ギー反応の原因となるロイコトリエンの産生を抑制する
効果のあることが報告されている（Ｐｒｏｓｔａｇｌａ
ｎｄｉｎ、第３６巻、第３号、１９８８年）。また、ド
コサヘキサエン酸（ＤＨＡ）やα−リノレン酸を含む油
脂の抗アレルギ−性（特開平２−２９０８１２号公報）
を利用した技術が知られている。しかし、これらの天然
の抗アレルギー剤は副作用が少ないものの、いずれもア
レルギー症状の予防および治療の効果がまだ充分とはい
えない。2. Description of the Related Art Allergic symptoms are caused by the production of immunoglobulin E (IgE) by an antigen-antibody reaction that occurs in the body, resulting in stimulation of the cell membrane of mast cells and release of histamine and leukotriene. These released substances have a function of promoting vascular permeability, a function of contracting smooth muscle, and the like, so that leukocytes and proteins leak from blood vessels, and inflammation causes contraction of the bronchi to cause asthma. Regarding antiallergic components, borneol has a mast cell membrane stabilizing ability (Japanese Patent Laid-Open No. 6-217113), and an anti-inflammatory action of actinomycete culture (Japanese Patent Laid-Open No. 2525).
A technology utilizing the Japanese Patent No. 053) is known. on the other hand,
It has been reported by Okuyama et al. That the intake of sesame oil has an effect of suppressing the production of leukotriene which causes allergic reaction (Prostagla).
ndin, Vol. 36, No. 3, 1988). Further, the antiallergic property of oils and fats containing docosahexaenoic acid (DHA) and α-linolenic acid (Japanese Patent Laid-Open No. 2-290812).
A technology utilizing is known. However, although these natural antiallergic agents have few side effects, none of them are sufficiently effective in preventing and treating allergic symptoms.
【０００３】アレルギー症状を軽減するために、従来よ
り、クロルフェニラミン、ジフェンヒドラミンなどの抗
ヒスタミン剤、クロモリン、トラニストなどの肥満細胞
膜安定剤、副腎皮質ホルモンなどを、経口投与により、
あるいは軟膏として用いてきた。しかしながら、抗ヒス
タミン剤は眠気や口渇などの副作用があり、肥満細胞膜
安定剤にはすでに起こってしまった症状を軽減する効果
は期待できない。副腎皮質ホルモンは、胃腸障害、肝臓
障害、糖尿病、高血圧などの副作用をともなう。これら
は、いずれも一時的な治療に用いられ、使用を中断すれ
ば再び症状がでるなどの問題があった。In order to reduce allergic symptoms, conventionally, antihistamines such as chlorpheniramine and diphenhydramine, mast cell membrane stabilizers such as cromolyn and tranisto, and adrenocortical hormones have been orally administered.
Or it has been used as an ointment. However, antihistamines have side effects such as drowsiness and thirst, and mast cell membrane stabilizers cannot be expected to have the effect of reducing already occurring symptoms. Corticosteroids are associated with side effects such as gastrointestinal disorders, liver disorders, diabetes and hypertension. All of these were used for temporary treatment, and there were problems such as reappearing symptoms if the use was stopped.
【０００４】竹抽出物は、食品保存料（特開昭５５−８
８６８７号公報）、静菌剤（特開昭６２−２３２３６４
号公報）、抗菌剤（特開昭６３−２９０８２５号公
報）、酸化防止剤（特開平１−２１３３８９号公報）な
どへの利用が提案されているが、竹抽出物の抗アレルギ
ー性については知られていなかった。Bamboo extract is a food preservative (see JP-A-55-8).
8687), a bacteriostatic agent (JP-A-62-232364).
No.), an antibacterial agent (Japanese Patent Laid-Open No. 63-290825), an antioxidant (Japanese Patent Laid-Open No. 1-213389), etc., but anti-allergic properties of bamboo extract are known. It wasn't done.
【０００５】[0005]
【発明が解決しようとする課題】本発明の目的は、上記
の薬剤による治療の問題点を解決するために、天然物か
らなる安全でしかも摂取しやすく、しかもアレルギー性
鼻炎（花粉症）やアトピー性皮膚炎等のアレルギー症状
の予防および治療剤を提供することにある。DISCLOSURE OF THE INVENTION The object of the present invention is to solve the above-mentioned problems of the treatment by the drug, and is safe and easy to ingest, which is a natural product, and allergic rhinitis (hay fever) and atopy. It is intended to provide a preventive and therapeutic agent for allergic symptoms such as dermatitis.
【０００６】[0006]
【課題を解決するための手段】本発明の第１は竹抽出物
を有効成分として含有する抗アレルギー剤であり、本発
明の第２は竹抽出物とω３系脂肪酸を含有する油脂から
なる抗アレルギー剤である。The first aspect of the present invention is an antiallergic agent containing a bamboo extract as an active ingredient, and the second aspect of the present invention is an antiallergic agent comprising a bamboo extract and an oil or fat containing an ω3 fatty acid. It is an allergic agent.
【０００７】[0007]
【発明の実施の形態】本発明の抗アレルギー剤に用いる
原料の竹としては、ホウオウチク属、シホウチク属、マ
ダケ属、シユドササ属、ササモルファ属、ナリヒラタケ
属、トウチク属などの竹類を用いることができ、中でも
マダケ属の孟宗竹およびハチクが特に好適である。本発
明ではこれらの竹を粉砕し、抽出しその抽出物を得る。
竹の使用する部位は葉、茎、根などであるが、茎の表皮
は抗アレルギー活性が高いので最も適している。本発明
において、竹から抗アレルギー活性を有する抽出物を得
るには、まず原料の竹の葉または茎の表皮をボールミル
等を用いて粉砕し、ついで、例えば、エタノール、ｎ−
ヘキサン、エーテル、アセトンなどの溶媒で抽出し、抽
出液を減圧下で加熱するなどにより溶媒を除去して、竹
抽出物を得ることができる。また、必要により、クロマ
トグラフィーなどにより、さらに精製することができ
る。得られた竹抽出物そのものをそのまま抗アレルギー
剤とすることもできるし、また竹抽出物を所定の油脂に
添加することにより、抗アレルギー剤を得ることができ
る。BEST MODE FOR CARRYING OUT THE INVENTION As the raw material bamboo used for the anti-allergic agent of the present invention, bamboos such as Pleurotus genus, Cynophorus genus, Physcomitrella genus, Pleurotus spp. Among them, Menso bamboo and Hachiku of the genus Bamboo are particularly preferable. In the present invention, these bamboos are crushed and extracted to obtain the extract.
Bamboo is used for leaves, stems and roots, but the epidermis of stems is most suitable because of its high anti-allergic activity. In the present invention, in order to obtain an extract having anti-allergic activity from bamboo, first, the raw leaves of bamboo leaves or stems are ground using a ball mill or the like, and then, for example, ethanol, n-
The bamboo extract can be obtained by extracting with a solvent such as hexane, ether, or acetone, and removing the solvent by heating the extract under reduced pressure. If necessary, it can be further purified by chromatography or the like. The obtained bamboo extract itself can be used as an antiallergic agent as it is, or an antiallergic agent can be obtained by adding the bamboo extract to a predetermined oil or fat.
【０００８】本発明で用いるω３系脂肪酸としては、例
えばαーリノレン酸、ドコサヘキサエン酸（ＤＨＡ）、
エイコサペンタエン酸（ＥＰＡ）等である。αーリノレ
ン酸を構成脂肪酸として含む油脂としては、例えばエゴ
マ油、シソ油等であり、ドコサヘキサエン酸（ＤＨＡ）
やエイコサペンタエン酸（ＥＰＡ）を構成脂肪酸として
含む油脂としては精製魚油、例えば、カツオ油やマグロ
油（ＤＨＡ油という）、サバ油、イワシ油（ＥＰＡ油と
いう）などがあり、さらにこれらを濃縮して使用するこ
ともできる。本発明の抗アレルギー剤は竹抽出物を直接
食品に混合、分散したのち、所望の形態に加工すること
により得ることができる。あるいは、竹抽出物をグリセ
リン脂肪酸エステル、プロピレングリコール脂肪酸エス
テル、ソルビタン脂肪酸エステル、ショ糖脂肪酸エステ
ル、レシチン、グリセリン等を使用して水に溶解して均
一な乳化状態にしてもよい。Examples of the ω3 fatty acid used in the present invention include α-linolenic acid, docosahexaenoic acid (DHA),
Examples thereof include eicosapentaenoic acid (EPA). Examples of fats and oils containing α-linolenic acid as a constituent fatty acid include sesame oil and perilla oil, and docosahexaenoic acid (DHA).
Examples of fats and oils containing eicosapentaenoic acid (EPA) as a constituent fatty acid include refined fish oils such as bonito oil, tuna oil (called DHA oil), mackerel oil, sardine oil (called EPA oil), etc. It can also be used. The antiallergic agent of the present invention can be obtained by directly mixing and dispersing the bamboo extract in a food product and then processing it into a desired form. Alternatively, the bamboo extract may be dissolved in water using glycerin fatty acid ester, propylene glycol fatty acid ester, sorbitan fatty acid ester, sucrose fatty acid ester, lecithin, glycerin or the like to obtain a uniform emulsified state.
【０００９】本発明の抗アレルギー剤の投与量は、成人
１日あたりの摂取量が竹抽出物換算で０．１〜１０ｇ
で、好ましくは０．５〜３ｇである。０．１ｇ未満では
アレルギー症状の予防および治療に効果が少なく、１０
ｇを超えると副作用のでる恐れがある。The dose of the antiallergic agent of the present invention is such that the daily intake of an adult is 0.1 to 10 g in terms of bamboo extract.
And preferably 0.5 to 3 g. Less than 0.1 g is less effective in preventing and treating allergic symptoms 10
If it exceeds g, side effects may occur.
【００１０】[0010]
【実施例】本発明を製造例、実施例、比較例および試験
例によりさらに詳細に説明する。 製造例１ 孟宗竹の茎１ｋｇをボールミルで粉砕し、エーテル５０
００ｍｌとともにソックスレー抽出器に仕込み、２０時
間加熱還流した。得られた抽出液を減圧乾固し、褐色の
竹抽出物４０．２ｇを得た。EXAMPLES The present invention will be described in more detail with reference to production examples, examples, comparative examples and test examples. Production Example 1 1 kg of Menso bamboo stalk was crushed with a ball mill to give 50 ethers.
It was charged into a Soxhlet extractor together with 00 ml and heated under reflux for 20 hours. The obtained extract was dried under reduced pressure to obtain 40.2 g of a brown bamboo extract.
【００１１】製造例２ ハチクの葉１ｋｇをボールミルで粉砕し、メタノール５
０００ｍｌを加えて１０日間放置した。得られた抽出液
を減圧乾固し、緑色の竹抽出成分４５．４ｇを得た。Production Example 2 1 kg of bee leaf was crushed with a ball mill, and methanol 5
000 ml was added and left for 10 days. The obtained extract was dried under reduced pressure to obtain 45.4 g of a green bamboo extract component.
【００１２】実施例１〜４、比較例１〜３ エゴマ油（日本油脂株式会社製品：αーリノレン酸含有
量５５重量％）、ＤＨＡ油（日本油脂株式会社製品：Ｄ
ＨＡ含有量２７重量％）、ＥＰＡ油（日本油脂株式会社
製品：ＥＰＡ含有量１３重量％）または製造例１の竹抽
出物を湯浴上で６０℃に加熱しながら攪拌均質化し表１
の配合によりＡからＤの単品の抗アレルギー剤を得た。
つぎに、これらをシームレスカプセル製造機（フロイン
ト産業株式会社製品）を使用して、１粒当たり各々２４
０ｍｇ含むＡからＤのゼラチンカプセルを調製した。さ
らに表１の配合による製造例１の竹抽出物とエゴマ油、
ＤＨＡ油またはＥＰＡ油とを湯浴上で６０℃に加熱しな
がら表１の配合により混合攪拌して均質化しＥからＧの
抗アレルギー剤を調製し、シームレスカプセル製造機に
より１粒当たり各々２４０ｍｇ含むＥ〜Ｇのゼラチンカ
プセルを製造した。これらのカプセルを用いて下記の試
験（試験例１）をおこなった。Examples 1 to 4 and Comparative Examples 1 to 3 Perilla oil (product of NOF Corporation: 55% by weight of α-linolenic acid content), DHA oil (product of NOF Corporation: D)
HA content of 27% by weight), EPA oil (Nippon Yushi Co., Ltd. product: EPA content of 13% by weight) or the bamboo extract of Production Example 1 was stirred and homogenized while heating at 60 ° C. in a hot water bath.
A single anti-allergic agent from A to D was obtained by blending.
Next, using a seamless capsule manufacturing machine (product of Freund Sangyo Co., Ltd.)
Gelatin capsules A to D containing 0 mg were prepared. Furthermore, the bamboo extract and the sesame oil of Production Example 1 having the formulations shown in Table 1,
Anti-allergic agents E to G are prepared by mixing and stirring DHA oil or EPA oil in a hot water bath at 60 ° C. according to the composition shown in Table 1 to homogenize, and each 240 mg is contained in one capsule by a seamless capsule manufacturing machine. EG gelatin capsules were prepared. The following test (Test Example 1) was performed using these capsules.
【００１３】[0013]
【表１】 [Table 1]
【００１４】実施例５〜８、比較例４〜６ 実施例１〜４に準じて、製造例２の竹抽出物を使用して
表２の配合により１粒当たり各々２４０ｍｇ含む抗アレ
ルギー剤を調製しＨからＮのゼラチンカプセルを製造し
た。これらのカプセルを用いて下記の試験（試験例２）
をおこなった。Examples 5 to 8 and Comparative Examples 4 to 6 According to Examples 1 to 4, the bamboo extract of Production Example 2 was used to prepare an antiallergic agent containing 240 mg per grain according to the formulation shown in Table 2. H to N gelatin capsules were prepared. The following test using these capsules (Test Example 2)
Was done.
【００１５】[0015]
【表２】 [Table 2]
【００１６】試験例１ 調整したカプセルＡ〜Ｇをアレルギー性鼻炎（花粉症）
患者からなる被験者７０名（男２８名、女４２名、２２
〜６３歳）をＡ群（実施例１：カプセルＡを投与）、Ｂ
群（比較例１：カプセルＢを投与）、Ｃ群（比較例２：
カプセルＣを投与）、Ｄ群（比較例３：カプセルＤを投
与）、Ｅ群（実施例２：カプセルＥを投与）、Ｆ群（実
施例３：カプセルＦを投与）、Ｇ群（実施例４：カプセ
ルＧを投与）の７群に分けて３ヶ月にわたつて投与して
臨床試験をおこなつた。Test Example 1 Prepared capsules A to G were used for allergic rhinitis (hay fever)
70 subjects consisting of patients (28 males, 42 females, 22
~ 63 years old) group A (Example 1: administration of capsule A), B
Group (Comparative Example 1: Administration of Capsule B), Group C (Comparative Example 2:
Capsule C is administered), Group D (Comparative Example 3: Capsule D is administered), Group E (Example 2: Capsule E is administered), Group F (Example 3: Capsule F is administered), Group G (Example) 4: Capsule G was administered) and divided into 7 groups for administration for 3 months to conduct a clinical test.
【００１７】臨床試験の方法については、花粉症状が患
者に現れた時から被験者に毎日１０錠ずつＡ〜Ｇのカプ
セルをＡ群〜Ｇ群のアレルギー性鼻炎（花粉症）患者に
経口投与した。一方、食事など生活活動は特に制限しな
かった。診断は試験開始日より１ヶ月後、２ヶ月後、３
ヶ月後の計３回実施した。なお、効果の判定は、被験者
の自覚症状をもとに、著効、有効、無効、悪化の４段階
で評価した。その結果を表１に示す。改善率は下記の式
により算定した。 改善率＝（著効＋有効）／総数×１００（％） これらの臨床試験の結果を表３に示した。Regarding the method of the clinical test, the subjects were orally administered with 10 capsules of AG each day to the patients of allergic rhinitis (hay fever) of groups A to G from the time when the symptoms of pollen appeared in the patients. On the other hand, daily activities such as eating were not limited. Diagnosis is 1 month, 2 months and 3 months after the start of the test.
It was carried out three times in total after a month. The effect was evaluated on the basis of the subjective symptoms of the test subject in four grades of excellent, effective, ineffective, and worse. Table 1 shows the results. The improvement rate was calculated by the following formula. Improvement rate = (Excellent response + Effective) / Total number × 100 (%) The results of these clinical tests are shown in Table 3.
【００１８】[0018]
【表３】 [Table 3]
【００１９】表１と表３の結果から、実施例１〜４
（Ａ、Ｅ、Ｆ、Ｇカプセル）の３ヶ月後の改善率が７０
％〜９０％であるのに対し、比較例１〜３（Ｂ、Ｃ、Ｄ
カプセル）ではそれが４０％〜５０％であり、本発明の
抗アレルギー剤が竹抽出物単品で花粉症の改善効果があ
り、さらに竹抽出物とエゴマ油、ＤＨＡ油またはＥＰＡ
油との混合品がそれぞれの単品よりも抗アレルギー活性
が強いことがわかる。From the results of Table 1 and Table 3, Examples 1 to 4
Improvement rate after 3 months of (A, E, F, G capsules) is 70
% To 90%, while Comparative Examples 1 to 3 (B, C, D
40% to 50%, and the antiallergic agent of the present invention is a bamboo extract alone and has an effect of improving hay fever, and further, the bamboo extract and perilla oil, DHA oil or EPA.
It can be seen that the mixed product with oil has stronger antiallergic activity than the individual products.
【００２０】試験例２ 試験例１に準じて、アトピー性皮膚炎患者からなる被験
者７０名（男４２名、女２８名 ５〜３２歳）をＨ群
（実施例５：カプセルＨを投与）、Ｉ群（比較例４：カ
プセルＩを投与）、Ｊ群（比較例５：カプセルＪを投
与）、Ｋ群（比較例６：カプセルＫを投与）、Ｌ群（実
施例６：カプセルＬを投与）、Ｍ群（実施例７：カプセ
ルＭを投与）、Ｎ群（実施例８：カプセルＮを投与）の
７群に分けて３ヶ月にわたつて投与して臨床試験をおこ
なつた。Test Example 2 According to Test Example 1, 70 subjects (42 males, 28 females, 5 to 32 years old) consisting of patients with atopic dermatitis were treated with H group (Example 5: Capsule H was administered), Group I (Comparative Example 4: Administration of Capsule I), Group J (Comparative Example 5: Administration of Capsule J), Group K (Comparative Example 6: Administration of Capsule K), Group L (Example 6: Administration of Capsule L) ), M group (Example 7: Capsule M administered) and N group (Example 8: Capsule N administered) were divided into 7 groups and administered for 3 months for clinical trial.
【００２１】試験方法についてはアトピー性皮膚炎が患
者に現れた時から被験者に毎日１０錠ずつＨ〜Ｎのカプ
セルをＨ群〜Ｎ群のアトピー性皮膚炎患者に経口投与し
た。一方、食事など生活活動は特に制限しなかった。診
断は試験開始日より１ヶ月後、２ヶ月、３ヶ月後の計３
回実施した。なお、効果の判定は、被験者の自覚症状を
もとに、著効、有効、無効、悪化の４段階で評価した。
その臨床の結果を表４に示す。Regarding the test method, from the time when atopic dermatitis appeared in the patient, the subjects were orally administered 10 capsules of H to N capsules daily to patients of atopic dermatitis of groups H to N. On the other hand, daily activities such as eating were not limited. Diagnosis is 1 month, 2 months, 3 months after the start of the test.
Times. The effect was evaluated on the basis of the subjective symptoms of the test subject in four grades of excellent, effective, ineffective, and worse.
The clinical results are shown in Table 4.
【００２２】[0022]
【表４】 [Table 4]
【００２３】表２と表４の結果から、実施例５〜８
（Ｈ、Ｌ、Ｍ、Ｎカプセル）の３ヶ月後の改善率が７０
％〜９０％であるのに対し、比較例４〜６（Ｉ、Ｊ、Ｋ
カプセル）ではそれが５０％であり、本発明の抗アレル
ギー剤が竹抽出物単品でアトピー性皮膚炎の改善効果が
あり、さらに竹抽出物とエゴマ油、ＤＨＡ油またはＥＰ
Ａ油との混合品がそれぞれの単品よりも抗アレルギー活
性が強いことが明らかになった。試験例１及び試験例２
の臨床試験の結果、本発明の抗アレルギー剤がアレルギ
ー性鼻炎（花粉症）やアトピー性皮膚炎のアレルギー症
状の改善効果があることがわかる。From the results of Tables 2 and 4, Examples 5-8
(H, L, M, N capsules) improvement rate after 3 months is 70
% To 90%, while Comparative Examples 4 to 6 (I, J, K
It is 50% in a capsule), and the antiallergic agent of the present invention is a bamboo extract alone and has an effect of improving atopic dermatitis. Furthermore, the bamboo extract and perilla oil, DHA oil or EP is used.
It was revealed that the mixed product with A oil had stronger antiallergic activity than the individual products. Test Example 1 and Test Example 2
As a result of the clinical test, it can be seen that the antiallergic agent of the present invention has an effect of improving allergic symptoms of allergic rhinitis (hay fever) and atopic dermatitis.
【００２４】[0024]
【発明の効果】本発明の抗アレルギー剤は、これまでの
抗炎剤、抗ヒスタミン剤などによる治療法とは異なり、
竹抽出物を有効成分として含んでいるため、成人の花粉
症や小児ではアトピー性皮膚炎に対する効果が大きく、
また竹抽出物とエゴマ油、ＤＨＡ油またはＥＰＡ油とを
併用すれば、その効果はさらに大きくなる。The anti-allergic agent of the present invention is different from the conventional treatment methods using anti-inflammatory agents, antihistamines, etc.
Since it contains bamboo extract as an active ingredient, it is highly effective against atopic dermatitis in adult hay fever and children,
Further, the combined use of the bamboo extract and the sesame oil, the DHA oil or the EPA oil will further increase the effect.
Claims (2)
レルギー剤。1. An antiallergic agent containing a bamboo extract as an active ingredient.
油脂からなる抗アレルギー剤。2. An anti-allergic agent comprising a bamboo extract and an oil or fat containing an ω3 fatty acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8087980A JPH09278662A (en) | 1996-04-10 | 1996-04-10 | Antiallergic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8087980A JPH09278662A (en) | 1996-04-10 | 1996-04-10 | Antiallergic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH09278662A true JPH09278662A (en) | 1997-10-28 |
Family
ID=13929982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8087980A Pending JPH09278662A (en) | 1996-04-10 | 1996-04-10 | Antiallergic agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH09278662A (en) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000046633A (en) * | 1998-12-31 | 2000-07-25 | 성재갑 | Composition for treatment of atopic dermatonosis |
| KR20040039663A (en) * | 2002-11-04 | 2004-05-12 | 최도성 | cosmectics for prerention and improvement of atopic dermatitis and manufacturing method therefor |
| EP1491203A4 (en) * | 2002-03-27 | 2007-07-18 | Hououdou Co Ltd | Compositions for treating and/or preventing pollenosis |
| US7569235B2 (en) | 2002-03-27 | 2009-08-04 | Hououdou Co., Ltd. | Compositions for treating and/or preventing pollinosis |
| US7897182B2 (en) | 2003-03-27 | 2011-03-01 | Unigen, Inc. | Composition comprising bamboo extract and the compounds isolated therefrom showing treating and preventing activity for inflammatory and blood circulation disease |
| US8247007B2 (en) | 2006-10-12 | 2012-08-21 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and Scutellaria |
| US9061039B2 (en) | 2002-03-01 | 2015-06-23 | Unigen, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
| US9370544B2 (en) | 2002-04-30 | 2016-06-21 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
| US9622964B2 (en) | 2003-04-04 | 2017-04-18 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
| JP2019123698A (en) * | 2018-01-19 | 2019-07-25 | 国立大学法人広島大学 | Antiallergic agent, and food, cosmetics, and pharmaceutical containing the same |
| JP2020145941A (en) * | 2019-03-12 | 2020-09-17 | 日本製粉株式会社 | Allergic rhinitis inhibitory composition |
-
1996
- 1996-04-10 JP JP8087980A patent/JPH09278662A/en active Pending
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000046633A (en) * | 1998-12-31 | 2000-07-25 | 성재갑 | Composition for treatment of atopic dermatonosis |
| US9061039B2 (en) | 2002-03-01 | 2015-06-23 | Unigen, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
| EP1491203A4 (en) * | 2002-03-27 | 2007-07-18 | Hououdou Co Ltd | Compositions for treating and/or preventing pollenosis |
| CN100400080C (en) * | 2002-03-27 | 2008-07-09 | 株式会社凤凰堂 | Compositions for treating and/or preventing pollinosis |
| US7569235B2 (en) | 2002-03-27 | 2009-08-04 | Hououdou Co., Ltd. | Compositions for treating and/or preventing pollinosis |
| US9849152B2 (en) | 2002-04-30 | 2017-12-26 | Unigen, Inc. | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent |
| US9370544B2 (en) | 2002-04-30 | 2016-06-21 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
| KR20040039663A (en) * | 2002-11-04 | 2004-05-12 | 최도성 | cosmectics for prerention and improvement of atopic dermatitis and manufacturing method therefor |
| US7897182B2 (en) | 2003-03-27 | 2011-03-01 | Unigen, Inc. | Composition comprising bamboo extract and the compounds isolated therefrom showing treating and preventing activity for inflammatory and blood circulation disease |
| US20110117224A1 (en) * | 2003-03-27 | 2011-05-19 | Unigen, Inc. | Composition Comprising Bamboo Extract and the Compounds Isolated Therefrom Showing Treating and Preventing Activity for Inflammatory and Blood Circulation Disease |
| US9622964B2 (en) | 2003-04-04 | 2017-04-18 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
| US8771761B2 (en) | 2006-10-12 | 2014-07-08 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
| US9623068B2 (en) | 2006-10-12 | 2017-04-18 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria |
| US8247007B2 (en) | 2006-10-12 | 2012-08-21 | Unigen, Inc. | Composition for treating atopic dermatitis comprising extracts of bamboo and Scutellaria |
| JP2019123698A (en) * | 2018-01-19 | 2019-07-25 | 国立大学法人広島大学 | Antiallergic agent, and food, cosmetics, and pharmaceutical containing the same |
| JP2020145941A (en) * | 2019-03-12 | 2020-09-17 | 日本製粉株式会社 | Allergic rhinitis inhibitory composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5945106A (en) | Montoxic extract of Larrea tridentata and method of making the same | |
| US20200113963A1 (en) | Aloe Preparation For Skin Enhancement | |
| US20190008907A1 (en) | Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases | |
| JP2010505944A (en) | Composition for the treatment of atopic dermatitis containing bamboo extract and Koganebana extract | |
| RU2657757C2 (en) | Novel extracts of cynara scolymus, coffea spp. and olea europaea for the treatment of metabolic syndrome | |
| EP3215169A1 (en) | Treatment of atopic dermatitis with indigo naturalis or indigo producing plant extract | |
| JPH09278662A (en) | Antiallergic agent | |
| JP2012515139A (en) | GIP elevation inhibitor | |
| KR20200136207A (en) | Composition for anti-allergy comprising extract of lithospermum erythrorhizon | |
| JPH04290822A (en) | Allergy preventing medicine and food | |
| KR20090084435A (en) | Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of houttuynia cordata thub and ulmus davidana var.japonica as an active ingredient | |
| JPH09291299A (en) | Antiallergic oil and fat composition and use | |
| US20080175888A1 (en) | Combination Therapy Comprising Actinidia and Steroids and Uses Thereof | |
| KR20040060808A (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
| WO2017173993A1 (en) | Orally administered essential oil composition and use thereof | |
| JPWO2006030907A1 (en) | Retinal protective agent | |
| JPH0662795A (en) | Antiallergic food | |
| WO2011042469A1 (en) | Use of a compound based on eremophilanolides | |
| JPH09187248A (en) | Antiallergic food | |
| JP2009185004A (en) | Agent for easing metabolic syndrome | |
| KR102598042B1 (en) | Composition having centipeda minima extracts for anti-inflammatory, preventing and curing autoimmune disease and manufacturing method thereof | |
| KR101576337B1 (en) | Composition for prevention or improving of inflammatory skin disease, or anti-oxidation comprising Zea mays leaves extract | |
| JP3936245B2 (en) | Antihypertensive | |
| KR102440534B1 (en) | Composition comprising a fraction of Sizigium formosium extract as an active ingredient | |
| JP2012530691A (en) | Method for isolating Shimiracemart A |